文献速递头颈部肿瘤放疗

德国非流行区鼻咽癌放疗患者内侧咽后淋巴结受累的多中心分析

Medial retropharyngeal lymph node involvement in nasopharyngeal cancer patients treated with radiotherapy in Germany - A multicenter analysis.
PubMed 文献 · Radiother Oncol · 2026-07-11

MERLIN回顾性多中心研究纳入德国9中心2004–2023年305例接受放疗或放化疗的鼻咽癌患者,中央 review 确认内侧咽后淋巴结(MRLN)受累率为2.95%(9/305),高于流行区报告的<1%。仅1例在既往照射且基线无MRLN受累的情况下出现内侧咽后间隙复发,提示非流行区患者经充分分期后省略MRLN预防照射似乎安全。

要点

  • 德国非流行区鼻咽癌队列MRLN受累率为2.95%(9/305),高于流行区<1%。
  • 70.2%(198/282)患者临床靶区包含MRLN,内侧咽后间隙复发仅1例。
  • 经充分分期后,非流行区鼻咽癌省略MRLN预防照射似乎安全。

核心结论

  • 德国非流行区鼻咽癌患者MRLN受累率高于流行区队列,但MRLN复发罕见,充分分期后省略MRLN预防照射似乎安全。

研究设计与样本

  • MERLIN研究(jARO-2025-05;DRKS00034782)是由young DEGRO试验组组织的回顾性多中心研究。
  • 纳入要求影像资料充分且组织学证实鼻咽癌并接受放疗或放化疗的患者,共评估9个中心2004–2023年治疗的305例患者。
  • 对怀疑MRLN受累的病例由委员会认证的放射科医生和放射肿瘤科医生进行中央 review。

主要发现

  • 305例患者中277例(90.8%)接受放化疗,28例(9.1%)接受单纯放疗;18.2%(55/302)接受新辅助化疗。
  • 21例怀疑MRLN受累,中央 review 确认9例,总受累率为2.95%(9/305)。
  • 70.2%(198/282)患者临床靶区包含MRLN;仅1例在既往MRLN照射且基线无MRLN受累情况下出现内侧咽后间隙复发。

关键数值与推荐

  • MRLN受累率2.95%(9/305),基于中央 review 确认。
  • 70.2%(198/282)患者临床靶区包含MRLN。
  • 内侧咽后间隙复发1例,发生于既往MRLN照射且基线无MRLN受累的患者。

临床怎么用

  • 对非流行区鼻咽癌患者,经充分影像分期排除MRLN受累后,可考虑省略MRLN预防照射。
  • 怀疑MRLN受累时应由放射科和放射肿瘤科医生中央 review 确认。

局限性

  • 回顾性多中心设计,MRLN受累基于影像怀疑并经中央 review 确认而非病理金标准。
  • 研究队列来自非流行区,结论外推至流行区需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVE: Prospective studies have demonstrated that involvement of medial retropharyngeal lymph nodes (MRLN) in endemic nasopharyngeal carcinoma (NPC) is rare, with a frequency below 1%. On this basis, a randomized trial demonstrated the oncological safety and improved quality of life after omission of radiotherapy (RT) to the MRLN in definitive chemoradiotherapy (CRT). Here, we evaluate the rate of MRLN involvement within a non-endemic cohort of NPC patients treated with RT/CRT in Germany. MATERIAL/METHODS: The MERLIN study (jARO-2025-05; DRKS00034782) is a retrospective multicenter study organized by the young DEGRO trial group. Patient inclusion required sufficient imaging and histologically proven NPC, treated with RT or CRT. Central review of cases, in which MRLN involvement was suspected, was performed by a board-certified radiologist and radiation oncologist. RESULTS: We evaluated 305 patients from 9 centers treated between 2004 and 2023. Patients were treated with CRT (n = 277, 90.8%) or RT alone (n = 28, 9.1%). Neoadjuvant chemotherapy was applied in 18.2% (55/302) of patients. MRLN involvement was suspected in 21 cases. Central review confirmed MRLN involvement in nine patients, yielding a total rate of 2.95% (9/305) across all patients. In 70.2% (198/282) of patients, MRLN were included in the clinical target volume. Only one recurrence occurred in the medial retropharyngeal space, despite prior MRLN irradiation and no baseline MRLN involvement. CONCLUSION: While involvement of MRLN was higher compared with cohorts from NPC-endemic regions, recurrence in MRLN was a rare event. After careful staging, omission of elective MRLN irradiation appears safe in NPC patients from non-endemic regions.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Kaufmann J, Nikolaidou E, Krabbes I, et al. Medial retropharyngeal lymph node involvement in nasopharyngeal cancer patients treated with radiotherapy in Germany - A multicenter analysis. Radiother Oncol. 2026. PMID: 42435818. doi:10.1016/j.radonc.2026.111696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。